The Drug That's Replacing Xylazine Is Already Winning, and Your Test Strip Can't See It

For a couple of years, harm reduction workers taught people to test for xylazine — “tranq” — the veterinary sedative that turned up in fentanyl and started causing wounds no one had seen before. That training is going stale fast. In Philadelphia, samples containing medetomidine — a different veterinary sedative, chemically related but far more potent — rose from 29% of the dangerous-adulterant supply in May 2024 to 90% by March 2026, while xylazine-positive samples fell from 97% to 28% over the same window, per the CDC’s Health Alert Network notice and STAT’s reporting. Nationally, DEA lab reports of medetomidine went from 247 in 2023 to 2,616 in 2024 to 8,233 in 2025 — a market that didn’t exist in any meaningful volume three years ago now dominating the sedative-adulterant supply in the places it’s been tracked.

Here’s the part that should change what you check for tonight: medetomidine is roughly 200 to 300 times more potent than xylazine by weight, it isn’t an opioid, and naloxone does nothing to reverse it. If you or someone with you is testing supply, a xylazine test strip won’t flag it — it’s a different molecule. The CDC’s field report on a Philadelphia cluster documented withdrawal that looked nothing like typical opioid withdrawal: severe hypertension, racing heart rate, delirium, and anxiety that standard opioid-withdrawal protocols aren’t built to manage, which means a person going through it — and the person trying to help them — may not recognize what’s happening or how to respond.

This is worth naming as a pattern, not a one-off. Crack down on one adulterant and the market doesn’t disappear, it substitutes: xylazine got scheduled state by state and enforcement leaned on it hard, and medetomidine filled the gap within eighteen months. STAT’s June reporting on nitazenes — synthetic opioids up to 40 times more potent than fentanyl, now confirmed in 48 states — describes the same dynamic one layer over: as countries crack down on nitazene precursors, traffickers are reportedly shifting toward an even newer, harder-to-detect class nicknamed “orphines” that neither fentanyl nor nitazene test strips catch.

If you use, or you’re keeping someone else safe while they do: the tools you were taught to trust two years ago are already behind the supply. That’s not a reason to stop testing — it’s a reason to ask your local harm-reduction program what’s actually showing up in results this month, because the strip in your pocket was designed for last year’s drug.